Ivermectin to Treat Cancer - Quick Reference Sheet

Ivermectin to Treat Cancer

Created on 09/27/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / GPT 6 – Audit

Ivermectin is a medicine for parasitic infections being researched for cancer. Human reports do not establish improved tumor control, survival, or quality of life. Short-course safety does not establish safety of sustained cancer use. Severe harm to the nervous system, liver injury, allergic reactions, and drug interactions are documented; replacing effective treatment adds risk. No validated cancer dose, duration, or monitoring target has emerged. (Full Review)

Protocol

Status of protocols
No validated cancer regimen
No published approach establishes an effective dose for ivermectin alone.
Dose-comparison research
Oral 200 or 400 micrograms/kg
ICONIC: once daily on days 1–3 weekly for four weeks with existing immune treatment; neither arm is an established cancer regimen.
Administration and food
Empty stomach with water
Oral label instructions; research food instructions take precedence within their protocol. No best time of day or benefit from split dosing is established.
Time to effect
Time to effect
No predictable time to tumor shrinkage or survival benefit is established.
Early subjective improvement and six-month cohort outcomes do not supply a reliable response timetable.

Benefits

Contraindications
  • Absolute contraindication: Known hypersensitivity to ivermectin or tablet components
  • Unestablished cancer use in pregnancy or breastfeeding
  • Unassessed high-burden Loa loa infection
  • Outside studied organ-function limits: ICONIC eligibility: creatinine clearance ≤30 mL/min; bilirubin >1.5× laboratory upper limit; liver enzymes >5× that limit with liver metastases (not universal safety cutoffs)
  • Bilirubin exception: ICONIC eligibility: bilirubin >3× laboratory upper limit in Gilbert syndrome
  • Children below 15 kg
Key Interactions
  • Warfarin — major caution: Breast-cancer trial excludes all use
  • Strong metabolic inhibitors — caution: CYP3A4: clarithromycin, itraconazole, ritonavir (ICONIC exclusion: seven days or five half-lives, whichever is longer)
  • Strong metabolic inducers — caution: CYP3A4: rifampin, carbamazepine, phenytoin (ICONIC exclusion: 14 days or five half-lives, whichever is longer)
  • Cancer medicines — caution: Regorafenib
  • Sedating medicines — caution: Opioids (morphine, oxycodone), sedating antihistamines (diphenhydramine, doxylamine), alcohol
  • Supplements — caution: St. John's wort, piperine (theoretical interactions)
  • Food — monitor: High-fat meals
  • Other cancer interventions — monitor: Surgery, radiation, chemotherapy, immune therapies

Risk & Side Effects

  • High: Digestive adverse effects; dizziness and reduced alertness; headache; muscle pain; inflammatory reactions to parasite killing; circulatory intolerance
  • Medium: Dose-related eye symptoms in onchocerciasis
  • Low: Severe neurological toxicity; liver injury; severe allergic skin and systemic reactions; bleeding with warfarin; asthma worsening; potential harm during pregnancy
  • Speculative: Loss of benefit from displaced cancer treatment; interference with anticancer immunity

Monitoring

Marker Target Why
Blood pressureBaseline comparisonEstablish safety context
Alanine and aspartate aminotransferasesNo established ivermectin-specific optimal target; baseline and laboratory upper limitsDetect liver injury
BilirubinNo established functional target; baseline and local reference intervalDetect liver dysfunction
AlbuminNo established anticancer target; baseline and nutritional contextInterpret binding and illness
Complete blood countNo established ivermectin-specific optimal range; baseline, symptoms, regimen thresholdsTrack blood-cell production (hemoglobin, neutrophils, platelets)
Creatinine and estimated kidney filtrationNo established functional target for ivermectin; baseline and trendAssess organ function
International normalized ratioIndividual anticoagulation target; commonly 2.0–3.0 for relevant warfarin indicationsDetect excessive anticoagulation
Pregnancy testNegative when required by protocolPrevent fetal exposure
Tumor imaging and disease-specific markersNo established ivermectin target; same lesions and appropriate baseline markersMeasure cancer course

Cadence: Baseline; pragmatic reassessment at 1–2 weeks, before each three-week cycle, and immediately for new symptoms; not an evidence-validated ivermectin schedule. Imaging and pregnancy retesting follow the study; warfarin checks follow the anticoagulation service.

Qualitative Assessment

  • Function and alertness: Walking, balance, wakefulness, concentration, daily activities. Symptoms and quality of life: Pain, appetite, bowel function, sleep, energy, treatment burden; validated cancer questionnaire where available. Attribution: Dated treatment changes and missed assessments.